Literature DB >> 15102475

JAK2 contributes to the intrinsic capacity of primary hematopoietic cells to respond to stem cell factor.

Nina Radosevic1, Dolores Winterstein, Jonathan R Keller, Hans Neubauer, Klaus Pfeffer, Diana Linnekin.   

Abstract

OBJECTIVE: Stem cell factor (SCF) is the ligand for the receptor tyrosine kinase (RTK) Kit. The literature contains conflicting reports regarding the capacity of SCF to activate JAK2. Previous work has addressed this controversial issue using biochemical approaches. Here we use a genetic approach to determine the direct role of JAK2 in SCF-mediated growth and differentiation of primary hematopoietic cells.
MATERIALS AND METHODS: Fetal liver cells were isolated from JAK2-deficient murine embryos at day 12 of development. SCF-induced growth and differentiation of this unfractionated population of cells were determined by 3H-thymidine incorporation in bulk cultures, single-cell colony assays, and cytochemistry. In addition, Kit+ cells were isolated from fetal liver by fluorescence-activated cell sorting (FACS) and assessed for growth using 3H-thymidine and colony assays.
RESULTS: SCF-induced growth of unfractionated JAK2-deficient fetal liver cells was reduced by 70% compared to cells from wild-type fetal liver in single-cell assays. This was of particular note because there were three-fold more Kit+ cells in JAK2-deficient fetal liver. Reductions in SCF-induced growth were not observed in bulk cultures of JAK2-deficient fetal liver, suggesting that additional factors cooperate with SCF to overcome the absence of JAK2 in this heterogeneous population of cells. SCF-induced 3H-thymidine incorporation of FACS-purified Kit+ fetal liver deficient for JAK2 was impaired by approximately 50%, whereas colony formation in methylcellulose was reduced 95%. JAK2 also was required for differentiation of this purified population of progenitors into mast cells.
CONCLUSION: JAK2 contributes to the intrinsic capacity of fetal liver hematopoietic progenitor cells to proliferate and differentiate in response to SCF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15102475     DOI: 10.1016/j.exphem.2003.11.006

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  10 in total

1.  Identification of a redox-sensitive switch within the JAK2 catalytic domain.

Authors:  John K Smith; Chetan N Patil; Srikant Patlolla; Barak W Gunter; George W Booz; Roy J Duhé
Journal:  Free Radic Biol Med       Date:  2012-01-15       Impact factor: 7.376

2.  Pathological interactions between hematopoietic stem cells and their niche revealed by mouse models of primary myelofibrosis.

Authors:  Lilian Varricchio; Annalisa Mancini; Anna Rita Migliaccio
Journal:  Expert Rev Hematol       Date:  2009-06-01       Impact factor: 2.929

Review 3.  JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications.

Authors:  Lorraine Springuel; Jean-Christophe Renauld; Laurent Knoops
Journal:  Haematologica       Date:  2015-10       Impact factor: 9.941

Review 4.  Tyrosine Kinase Inhibitors and Therapeutic Antibodies in Advanced Eosinophilic Disorders and Systemic Mastocytosis.

Authors:  Jason Gotlib
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

5.  High-resolution kinetics of cytokine signaling in human CD34/CD117-positive cells in unfractionated bone marrow.

Authors:  Philip G Woost; Luis A Solchaga; Howard J Meyerson; T Vincent Shankey; Charles L Goolsby; James W Jacobberger
Journal:  Blood       Date:  2011-02-17       Impact factor: 22.113

6.  Friend spleen focus-forming virus transforms rodent fibroblasts in cooperation with a short form of the receptor tyrosine kinase Stk.

Authors:  Kazuo Nishigaki; Charlotte Hanson; Tanya Jelacic; Delores Thompson; Sandra Ruscetti
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-13       Impact factor: 11.205

Review 7.  The JAK/STAT signaling pathway: from bench to clinic.

Authors:  Xiaoyi Hu; Jing Li; Maorong Fu; Xia Zhao; Wei Wang
Journal:  Signal Transduct Target Ther       Date:  2021-11-26

8.  Stat5 activation enables erythropoiesis in the absence of EpoR and Jak2.

Authors:  Florian Grebien; Marc A Kerenyi; Boris Kovacic; Thomas Kolbe; Verena Becker; Helmut Dolznig; Klaus Pfeffer; Ursula Klingmüller; Mathias Müller; Hartmut Beug; Ernst W Müllner; Richard Moriggl
Journal:  Blood       Date:  2008-01-31       Impact factor: 22.113

9.  Thrombocytosis: diagnostic evaluation, thrombotic risk stratification, and risk-based management strategies.

Authors:  Jonathan S Bleeker; William J Hogan
Journal:  Thrombosis       Date:  2011-06-08

10.  Ruxolitinib for the treatment of myelofibrosis: its clinical potential.

Authors:  Alen Ostojic; Radovan Vrhovac; Srdan Verstovsek
Journal:  Ther Clin Risk Manag       Date:  2012-03-01       Impact factor: 2.423

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.